BOISE, ID / ACCESSWIRE / March 10, 2016 / U.S. Geothermal Inc. (NYSE MKT: HTM) (TSX: GTH) will host a conference call and live webcast to discuss the results of the fourth quarter and fiscal year 2015, to be held Friday, March 11, 2016 at 1:00 PM Eastern Time.

To participate in this event, dial 877-407-8133 domestically, or 201-689-8040 internationally, approximately 5 to 10 minutes before the beginning of the call. Additionally, you can listen to the event online at www.investorcalendar.com/IC/CEPage.asp?ID=174757.

If you are unable to participate during the live webcast, the event archive will be available at www.investorcalendar.com.

About U.S. Geothermal Inc.

U.S. Geothermal Inc. is a leading and profitable renewable energy company focused on the development, production and sale of electricity from geothermal energy. The company is currently operating geothermal power projects Neal Hot Springs, Oregon, San Emidio, Nevada and Raft River, Idaho for a total power generation of approximately 45 MWs. The company is also developing projects at: The Geysers, California; a second phase project at San Emidio, Nevada; the El Ceibillo project located near Guatemala City, Guatemala; and at Crescent Valley, Nevada. U.S. Geothermal’s growth strategy is to reach 200 MWs of generation by 2020 through a combination of internal development and strategic acquisitions.

SOURCE: Investor Calendar

ReleaseID: 437701

SEATTLE, WA / ACCESSWIRE / March 10, 2016 / It takes more than a few company policies to be held as an example of how to do business the right way. It takes more than a couple of company leaders to increase an ethical reputation. What it takes is a strong ethical culture that is so fully intertwined with everyday business practices that doing the right thing is never questioned.

At 3M, ethical standards are woven throughout the science-based company’s core, from its Company Vision, to its Code of Conduct and the Leadership Behaviors that all employees must demonstrate in their annual review. 3M’s ethical culture has strengthened during its 114-year history and is setting an example for businesses around the world.

“3M’s people are the champions for our Code of Conduct and embody the company’s longstanding commitment to ethics and integrity,” said Kristen Ludgate, 3M’s vice president, Associate General Counsel and chief compliance officer. “Together, 3M teams create trust with customers and value for shareholders by doing business the right way, every day and everywhere in the world. Our Code of Conduct is a core part of 3M’s business playbook and is integral to advancing 3M’s corporate vision to improve every life.”

This is why Ethisphere, a global leader in defining and advancing the standards of ethical practices in business, has listed 3M as a World’s Most Ethical Company for a third year in a row. The organization recognizes companies who align principle with action, work tirelessly to make trust part of their corporate DNA, and in doing so shape future industry standards by introducing tomorrow’s best practices today.

“3M’s 100-plus years demonstrate a sustainable business advantage that is supported by their values and commitment to ethics and innovation,” explained Ethisphere’s Chief Executive Officer, Timothy Erblich. “They clearly understand their role in the broader global business community and recognize the value of operating with integrity. Congratulations to everyone at 3M for being recognized as a 2016 World’s Most Ethical Company.”

Ethisphere assesses companies around the world in five categories: ethics and compliance program, citizenship and corporate responsibility, culture of ethics, governance, and leadership, innovation and reputation. 3M scored high marks in all categories, but particularly well in citizenship and corporate responsibility.

The full list of the 2016 World’s Most Ethical Companies can be found at: http://worldsmostethicalcompanies.ethisphere.com/honorees.

You can learn more about 3M’s Bair Hugger Products

http://www.nurses.com/doc/bair-hugger-therapy-0001
http://www.bairhuggerfacts.com/

About 3M

At 3M, we apply science in collaborative ways to improve lives daily. With $30 billion in sales, our 90,000 employees connect with customers all around the world. Learn more about 3M’s creative solutions to the world’s problems at www.3M.com or on Twitter @3M or @3MNewsroom.

SOURCE: Emerald City Journal

ReleaseID: 437704

VANCOUVER, BC / ACCESSWIRE / March 10, 2016 / Brigade Resource Corp. (“Brigade”) is pleased to announce amendments to the terms of its previously announced private placement (the “Private Placement“). Pursuant to the amended Private Placement, the Company is offering up to 5,000,000 units at a price of $0.10 per unit for aggregate gross proceeds of up to $500,000.

Each unit will consist of one common share (a “Share“) and one two-year share purchase warrant entitling the holder to acquire one additional Share at a price of $0.15 per Share for the first 12 months from the date of issue, followed by $0.20 per Share thereafter. All other terms of the Private Placement are unchanged.

For more information, please contact:

Glenn Little, CEO
Brigade Resource Corp.
(604) 559.3390
glenn@brandenburgfincorp.com

Forward-Looking Information:

This press release may include forward-looking information within the meaning of Canadian securities legislation, relating to the private placement including its terms and conditions. The forward-looking information is based on certain key expectations and assumptions made by the management of Brigade Resource Corp. Although the company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the company cannot provide any assurance that it will prove to be correct. These forward-looking statements are made as of the date of this press release and the company disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF U.S. SECURITIES LAWS.

SOURCE: Brigade Resource Corp.

ReleaseID: 437703

NEW YORK, NY / ACCCESSWIRE / March 9, 2016 / Mike Chang, Holder of YouTube’s biggest fitness channel released his new training program for reducing belly fat and forming abs within a week. The program offers simple fitness tips swapping tough workouts. This Report Uncovers Important Aspects of Six Pack Shortcuts.

A new fitness program named “Six Packs Shortcut” has recently hit the market, grabbing massive attention of people due to the name of its creator Mike Chang who is the most famous fitness trainer on You Tube with over 3.5 million subscribers on his channel.”Six Packs Shortcut” is actually a written compilation and presentation of his latest fitness training course aiming to reduce belly fat fast and help attain people six packs with a toned, muscular body in few days.

Mark Simone from Healthy Nutrition reports his latest findings on Six Packs Shortcut

According to Mark, “Six Packs Shortcut by Mike Chang contributes in the effectiveness of all existing fitness programs in the market as Chang has revealed minor changes that can make a simple workout give great results to the person who seek to attain a muscular, in-shape and toned body. Mike’s approach to achieve a muscular body is simple as he focuses in improving and simplifying the conventional form of exercises and making them more effective in a way that the results come faster and sustain for longer period.”

The plan focuses on simple movements of the body to be set up properly for people to understand and carry out. Movements such as daily walk, stretching of muscles, neck, hand and legs light movements for 2 minutes and magical recipes of juices that can burn belly fat drastically. People would be taught to carry out these exercises at home as per the requirements of their physique.

Mike explains that it isn’t necessary that a weight loss plan works for all body types. Some physiques need a different way to handle their weight loss depending upon their type of body, their food intake and their lifestyle. Six Pack Shortcuts contains information that helps people to identify their body type and choose the best workout suiting their requirements. In this way, Six Pack Shortcuts’ strategies were observed to be more effective than other workout plans. Reduction of belly fat, building up muscles and abs and thinning the waistline for a toned appearance is what this plan is all about.

Access The News Report by Mark Simone Exposing The Breakthrough Ab Training Method by Mike Chang

Mark further states, “Six Pack Shortcuts program is presented in both manual and visual format for the maximum ease of the users to understand every exercise and fitness strategy properly and face no hurdles in the executing the plan. The program consists of two phases, dealing with different body parts and their exercises. First phase has four lessons with a quick startup workout leading to the other body exercises aiming to burn calories and activating muscles. There are lessons solely aiming to burn calories from arms, tummy, butt and thighs.”

Each exercise is designed to maximize the chances of fat reduction with easy efforts. This phase also has a video library having important factual information and instructions to reduce belly fat and achieve abs, also the exercises that turns the starvation mode on in the body so that the body utilizes the stored fat for energy production instead of craving for more food. These exercises help in reducing face, arms and thigh fat as well. In addition, this phase contributes a complete lesson for building up six packs in few days.

Mike names this fitness strategy as belly fat blaster which is considered to be highly effective in trimming the tummy and forming abs with a thin waistline. The exercises work real quick to achieve the desired results by strengthening abdominal muscles, draining out the stored fat through belly sweating and secretion of body skin. This part works for men and women both in killing belly fat and attaining a slim and toned belly.

READ MORE – Follow These Tips to Develop Your Hard-To-Define Lower Abs

As the first phase covers the edge areas of the body storing fats, the second phase covers the front and back of a person’s midriff and works to strengthen the adjoining muscles of that part of the body. This phase is long as it covers the whole body fitness training along with numerous fitness tips and tricks. It contains exactly 14 lessons with 56 video tutorials and some scripts as well.

One of the secret tips that have been exposed through latest reviews is that Mike breathing exercise in which body can naturally trigger a phenomenon to form abs by strengthening the belly muscles and protecting the lower back. This exercise can be done just by exhaling air deeply as mentioned in the program and within a week, it said that it will make the abs prominent.

Six Pack Shortcuts program is also famous for its series of core stabilization exercises to prevent the muscles from any sort of injury. This is actually a safety measure that a user should take while doing any exercise so that no part of the body gets damaged. Core stabilizing not just prevents injuries but also really for burning calories. Every exercise, workout tip and information is a shortcut to bigger and complicated fitness plans as Mike was able to simplifying the tricky and exhausting workout plans into simple fitness shortcuts.

The main manual video of the program has four levels with an MP3 as well which can be listened while a person is on walk or relaxing on couch, it is basically designed for motivation and developing will power. All the four levels are about preparing the body to brace the change in its physique and works further to achieve a muscular and toned body by following simple shortcut exercises that takes only 5 minutes of daily routine. Level three and four works to reduce belly fat, build up muscles and abs and finally polishing the body’s shape into a perfectly toned physique. The whole process takes 10 days and can be repeated if needed.

Visit The Official Website of Six Pack Shortcuts By Mike Chang

Six Packs Shortcuts also has a list of items that are proven shortcut diets for a healthy and in-shape body. These ingredients are easily available at any grocery store and can be used in thousands of recipes. Mike has included some in his plan along with links where more recipes can be taken from. “Shortcut diets are as simple and effective as shortcut exercises are,” says Mike.

To conclude his review, Mark states, “Six Pack Shortcut is the first such installment by Mike Chang that compiles his secrets about abs in a digital manual and video. In Steve Harvey’s show, it was considered to be the most reliable fitness shortcut program these days when life is really fast and people hardly gets time to pay attention to their fitness. Six Pack Shortcuts is available in a very affordable price on its official website. Mike has also offered 60 days money refund in case of user’s dissatisfaction. For more information, visit their website or contact their active customer support service.” Local 800-655-8576 Email admin@sixpackshortcuts.com.

About Healthy Nutrition

Healthy Nutrition is an independently owned company situated in New York, NY that assists consumers to find user-based information on specified products and services to help individuals determine if those specific products and services are in fact a suitable fit for them.

CONTACT INFORMATION

Mark Simone
Healthy Nutrition
Mark@healthynutrition.co

SOURCE: Healthy Nutrition

ReleaseID: 437674

Invented and Made In the USA, ECO Funnel Is Now the Standard for Handling Volatile Toxic Waste in the Laboratory

NOVATO, CA / ACCESSWIRE / March 10, 2016 / CP Lab Safety (www.cplabsafety.com) salutes Dr. Ron Najafi, inventor of ECO Funnel®, and celebrates 20 years of environmental activism and stewardship on March 13, 2016.

Back in the 1990s, CP Lab Safety founder Dr. Ron Najafi realized that open waste containers and inappropriate chemical waste handling in laboratories were serious health and safety issues. Scientists were being exposed to toxic fumes and labs were being contaminated. In addition, the volatile chemicals evaporating in the air elevated the risk of fire.

As a solution to these problems, Ron invented the Safety Ecological Funnel. His funnel trapped fumes from open containers, allowing almost any container to become a safe, easy and contained temporary storage solution for waste chemicals.

Ron initially tried to license his invention to other lab safety manufacturers, but no one was interested. He was told that there was no market for such a product, and that scientists don’t care about open waste containers. They said it was best to let laboratory waste evaporate and pollute the environment and claimed that the ECO Funnel solution was ‘anti-business’ since labs would have to spend money to collect waste and dispose of it properly.

With no takers, Ron decided to promote the ECO Funnel on his own. He left his job as a synthetic organic chemist at Applied Biosystems and formed CP Lab Safety Inc. in the basement of his house on March 13, 1996.

Ron was quickly proven to be on the right side of history. As public awareness to environmental pollutants rose, ECO Funnel became a key product for containing those pollutants, reducing the exposure of workers to hazardous substances and eliminating flammable fumes from the workplace. Here are just two of the many accolades that the product has received:

“The Safety ECO Funnel is an ideal containment system that eliminates the danger of ignited vapors and spills from open chemical waste containers.” – Steve Carrol, San Diego Fire Marshal and Biotech Inspector

“The ECO Funnel has helped us meet environmental Regulator requirements while at the same time provide added protection of spill prevention from handling operations and waste streams from equipment.”– Don Pearson, Roche Diagnostics

For CP Lab Safety, the ECO Funnel was just the beginning. Over the last 20 years, the company has expanded its product line to include thousands of products, including lab bottles, lab containers & safety containers, lab glassware, chemistry supplies, Eagle® & Justrite® safety storage cabinets, safety cans, Nalgene® labware, carboys, safety coated glass bottles, vials, and industrial safety supplies.

In December of 2000 Ron Najafi officially started NovaBay Pharmaceuticals and left the day-to-day management of CP Lab Safety to the current CEO, Kelly Farhangi. Kelly and her team moved manufacturing for all ECO Funnel products back to the USA from China, improving quality and actually lowering manufacturing costs. Today CP Lab Safety distributes over 17,000 products worldwide. CP Lab Safety is also registered in the State of California as a Woman Owned Business and a California State Certified Small Business, and a GSA Contractor, providing the company with more avenues in which to spread environmentally sound business practices.

More on Dr. Ron Najafi at: https://en.wikipedia.org/wiki/Ron_Najafi
More on ECO funnel at: https://en.wikipedia.org/wiki/Eco_funnel

Media Contact:

Kelly Farhangi,
President & CEO
415-225-9868
kelly@cplabsafety.com
www.cplabsafety.com

SOURCE: CP Lab Safety

ReleaseID: 437697

NEW YORK, NY / ACCESSWIRE / March 10, 2016 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it has issued an update note on Amarantus BioScience Holdings, Inc. (OTCQX: AMBS).

The report is available here: AMBS March 2016 Update Note. SeeThruEquity is an approved equity research contributor on Thomson First Call, Capital IQ, FactSet, and Zack’s. The report will be available on these platforms. The firm also contributes its estimates to Thomson Estimates, the leading estimates platform on Wall Street.

Highlights from the note are as follows:

Avant Diagnostics and Amarantus Diagnostics to combine operations with Theranostics Health

Amarantus Diagnostics, a wholly-owned subsidiary of Amarantus BioScience Holdings, and Avant Diagnostics announced they have jointly entered into a Letter of Intent for Avant to acquire assets and certain liabilities of Theranostics Health Incorporated. The combination will add key CLIA laboratory and intellectual property capabilities to the impending merger between Amarantus Diagnostics and Avant Diagnostics. According to the LOI, upon closing Avant will issue to Theranostics 25 million shares and Amarantus has provided a $400,000 convertible note. The transaction is expected to close in the first half of 2016.

Theranostics works with 7 of the 10 largest pharmaceutical companies (based on revenue) and generates over $1.5mn in services revenue. Theranostics business is centered on providing pharmaceutical and biotechnical companies access to its technology for qualitatively measuring the activation status of key proteins and signal transduction pathways that are dysregulated in multiple disease processes via its Reverse-phase Protein Array (RPPA) platform.

The combined company will have a robust pipeline of oncology and neurology diagnostics, with 3 proprietary diagnostic tests for ovarian cancer, multiple sclerosis, and Alzheimer’s disease. In 2016, CLIA-enabling validation studies are expected to be initiated for OvaDx, MSPrecise and LymPro Test, with product launch in 2017. The scientific focus is on becoming a recognized leader in the field of cell cycle biology research, driven largely by Theralink for oncology and LymPro Test for Alzheimer’s.

Orphan drug designation for eltoprazine

The Company announced on February 10, 2016, that it has received orphan drug designation from the US FDA for eltoprazine in the treatment of Parkinson’s disease levodopa-induced dyskinesia (PD-LID).

Rare pediatric disease designation request

AMBS recently announced that it has requested Rare Pediatric Disease Designation (RPDD) from the US Food and Drug Administration (FDA) for treating retinitis pigmentosa (RP) with MANF.

European patents for Amarantus’ Engineered Skin Substitute

The Cutanogen Corporation, a wholly owned subsidiary of AMBS, has announced on February 3, 2016, that it has received 2 Intent to Grant a Patent notices from the European Patent Officer for Engineered Skin Substitute (ESS). The notices cover the parent patent application entitled “A method of producing a cultured skin device” and an associated divisional patent filing. The Company expects both patents to be issued later in 2016 and to add key elements to their barrier-to-entry strategy for this technology.

Issuance of Chinese patent

On January 29, 2016, the Company disclosed the issuance of a Chinese patent named “Neurodegenerative Disorders” that it is for the use of MANF for the treatment of Parkinson’s disease and other neurodegenerative conditions. The patent also covers MANF protein therapy, gene therapy and cell therapy applications into 2029.

New investments

The Company recently announced the closing of a $3mn investment, and a $1mn investment from an investor introduced by International Infusion, LLC.

Please review important disclosures at www.seethruequity.com.

About Amarantus BioScience Holdings, Inc.

Amarantus BioScience Holdings (AMBS) is a biotechnology company developing treatments and diagnostics for diseases in the areas of neurology and orphan diseases. AMBS’ Therapeutics division has development rights to eltoprazine, a small molecule currently in a Phase 2b clinical program for Parkinson’s disease levodopa-induced dyskinesia and with the potential to expand into adult ADHD and Alzheimer’s aggression. The Company has an exclusive worldwide license to intellectual property rights associated to Engineered Skin Substitute (ESS), an orphan drug designated autologous full thickness skin replacement product in development for the treatment of severe burns currently preparing to enter Phase 2 clinical studies. AMBS owns the intellectual property rights to a therapeutic protein known as mesencephalic-astrocyte-derived neurotrophic factor (MANF) and is developing MANF as a treatment for orphan ophthalmic disorders, initially in retinitis pigmentosa (RP). AMBS also owns the discovery of neurotrophic factors (PhenoGuard(TM)) that led to MANF’s discovery.

AMBS’ Diagnostics division owns the rights to MSPrecise(R), a proprietary next-generation DNA sequencing (NGS) assay for the identification of patients with relapsing-remitting multiple sclerosis (RRMS) at first clinical presentation, has an exclusive worldwide license to the Lymphocyte Proliferation test (LymPro Test(R)) for Alzheimer’s disease, which was developed by Prof. Thomas Arendt, Ph.D., from the University of Leipzig, and owns intellectual property for the diagnosis of Parkinson’s disease (NuroPro).

For further information please visit www.Amarantus.com, or connect with the Company on Facebook, LinkedIn, Twitter and Google+.

About SeeThruEquity

SeeThruEquity is an equity research and corporate access firm focused on companies with less than $1 billion in market capitalization. The research is not paid for and is unbiased. The company does not conduct any investment banking or commission based business. SeeThruEquity is approved to contribute its research to Thomson One Analytics (First Call), Capital IQ, FactSet, Zacks, and distribute its research to its database of opt-in investors. The company also contributes its estimates to Thomson Estimates, the leading estimates platform on Wall Street.

For more information visit www.seethruequity.com.

Contact:

Ajay Tandon
SeeThruEquity
info@seethruequity.com

SOURCE: SeeThruEquity

ReleaseID: 437699

NEW YORK, NY / ACCESSWIRE / March 10, 2016 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it has initiated coverage on Avant Diagnostics, Inc. (OTCQB: AVDX) with a price target of $2.97.

The report is available here: AVDX Initiation Report. SeeThruEquity is an approved equity research contributor on Thomson First Call, Capital IQ, FactSet, and Zack’s. The report will be available on these platforms. The firm also contributes its estimates to Thomson Estimates, the leading estimates platform on Wall Street.

Avant Diagnostics’ solution is to utilize the technology that it exclusively licensed from Wayne State University and seek the new research methods in the diagnostics industry. The Company’s goal is to commercialize microarray-based diagnostic tests and services that aim to detect diseases at an early-stage with pre-symptomatic screening. These novel methods are based on patented and proprietary techniques that are suitable to be run in a central or regional laboratory utilizing samples from healthcare providers in the U.S. and sent to the authorized CLIA/ISO-certified testing facility for future research. Avant’s goal is to become a leading facility in the early-detection process by building a pipeline of 4-6 diagnostic tests in 12-18 months through organic development and acquisitions of other techniques focused on early detection and pre-symptomatic screening.

“According to BCC Research, a leading publisher of technology market reports, the global ovarian cancer drug and the diagnostic market will be reaching $34.6 billion by 2018, representing a compound annual growth rate of 13.1% between 2013 and 2018. The primary driver for this market is the high prevalence of ovarian cancer among women. Ovarian cancer is associated with high morbidity and mortality rate because the majority of patients are diagnosed at a later stage. The survival rate drops significantly as the current medical treatments fail to detect ovarian cancer at an early stage. Early detection has a 5-year survival rate of 93%, but late-stage symptoms only have a 5-year survival rate of 18%. The lack of early symptoms and effective diagnostic tests make ovarian cancer the 5th most common cancer in the U.S. Avant’s sophisticated product, OvaDx®, can potentially mitigate this issue by detecting an ovarian tumor in the early stage, which will significantly increase survival rates,” commented Ajay Tandon, CEO of SeeThruEquity. “We are initiating coverage with a 12-month price target of $2.97 per share.”

Additional highlights from the report are as follows:

Large addressable market

Avant Diagnostics has identified a large, addressable market – namely a $34.6 billion ovarian cancer drug and diagnostics market. Ovarian cancer is the 5th most common cancer in the U.S, and ~20,000 women will be diagnosed with ovarian cancer annually. Avant Diagnostics’ main product aims to detect an ovarian tumor in its early stage using microarray-based techniques, which can significantly increase the cure and survival rates for ovarian cancer patients.

Impending merger with Amarantus Diagnostics

Amarantus Bioscience Holdings, Inc. (OTCQX: AMBS), a biotechnology company that develops medical treatments that focus on Regenerative Medicine, Neurology and Orphan diseases, announced that it has entered into a Letter of Intent to acquire and merge its wholly-owned subsidiary, Amarantus Diagnostics, into Avant Diagnostics. The merger will create mutual benefits, as AMBS will assist AVDX to further commercialize resources, to accelerate the monetization of the products and Avant will improve AMBS’s technology in the diagnostic industry.

AVDX and Amarantus Diagnostics to combine with Theranostics Health

Avant and Amarantus Diagnostics, a wholly-owned subsidiary of Amarantus BioScience Holdings, announced they have jointly entered into a Letter of Intent for Avant to acquire assets and certain liabilities of Theranostics Health Incorporated. The combined company will have a robust pipeline of oncology and neurology diagnostics, with 3 proprietary diagnostic tests for ovarian cancer, multiple sclerosis, and Alzheimer’s disease. The business combination would have 7 of top 10 pharmaceutical companies as customers and the possibility of $1.5M in revenue in 2016. The combined entity would also provide a sales channel for the Alzheimer LymPro Test.

Strong patent positions

Based on 10+ years of research and development, Avant has exclusive license rights to the trade secrets and protocols required for the sale and use of the OvaDx® ovarian cancer test.

Please review important disclosures at www.seethruequity.com.

About Avant Diagnostics, Inc.

Avant Diagnostics’ solution is to utilize the technology that it has exclusively licensed from Wayne State University to exploit the new opportunities in the diagnostics industry. The Company was created to specifically commercialize microarray-based diagnostic tests and services that are focused on early detection and pre-symptomatic screening. These new tests are based on patented and proprietary technology that is suitable to be run in a central or regional laboratory utilizing samples that are collected by healthcare providers and sent to the authorized CLIA/ISO-certified testing facility for processing.

For more information, please visit the Company’s website at www.avantdiagnostics.com.

About SeeThruEquity

SeeThruEquity is an equity research and corporate access firm focused on companies with less than $1 billion in market capitalization. The research is not paid for and is unbiased. The company does not conduct any investment banking or commission based business. SeeThruEquity is approved to contribute its research to Thomson One Analytics (First Call), Capital IQ, FactSet, Zacks, and distribute its research to its database of opt-in investors. The company also contributes its estimates to Thomson Estimates, the leading estimates platform on Wall Street.

For more information visit www.seethruequity.com.

Contact:

Ajay Tandon
SeeThruEquity
info@seethruequity.com

SOURCE: SeeThruEquity

ReleaseID: 437698

NEW YORK, NY / ACCESSWIRE / March 10, 2016 / Big data, faster and more efficient communication and improved technological infrastructure are all going to play a key role in the next big web-based revolution – the internet of things. As companies like Alphabet Inc. (NASDAQ: GOOG) and Samsung Electronics Co. Ltd. (OTCMKTS: SSNLF) rush to take a leadership position in the space, smaller, less well known companies are drawing collateral benefit from the advances. As IoT coalesces, there is a good possibility of substantial roll-up of smaller firms by the current tech leaders with more than a tad of interest in the space. Here are 4 possible targets to keep an eye on for the near future.

RadiSys Corporation (NASDAQ: RSYS)

RadiSys specializes in what’s called Small Cell Offloading. Because of the huge increase in mobile data transfer via tablets and cell phones, the current infrastructure is struggling to keep up. Small cell offloading is a way to take the load off networks such as 3G, 4G and LTE, freeing up space for added use. They are smaller than the macrocells currently used for this sort of offloading (range is measured in meters for small cells versus kilometers for macrocells) but they are ideal for office buildings, homes etc., and are much more efficient than their larger counterparts.

It’s a space that analysts expect to grow exponentially over the next few years, slated to generate revenues of $1.2 billion next year and $6.5 billion between now and 2019, and RadiSys is a leader in the sector, having provided behemoths such as Intel Corporation (NASDAQ: INTC) and QUALCOMM Incorporated (NASDAQ: QCOM) with small cell technology. With 2015 financials just around the corner and a recent analyst upgrade, it’s one to watch.

Sysorex Global (NASDAQ: SYRX)

Sysorex has three main focus areas – location technology, data analytics and migration, and electronic publishing. It generated $63 million revenues in 2014 from a range of private, commercial and government contracts, and during the first three quarters of 2015, recorded just shy of $50 million in revenues. At last count, it had a little over $5 million cash with a further $11 million in net receivables, which have likely realized by now, yet its market capitalization is just $13 million. From a value perspective, a company that has its entire market capitalization held in cash and generates 4-5 times multiple of its market cap in revenues each year looks like a good deal.

The core technology on which the company relies, and the technology from which it generates the majority of its revenues is its LightMiner platform. It’s one of the only technologies in the world that can absorb every type of data and provide conversion and visualization in real time, so it could end up playing a big part in the booming big data space going forward. Big data, in turn, will form the basis of the IoT, which is estimated to grow to a gargantuan $1.7 trillion in revenue by the end of the decade. Sysorex is an off the radar stock, well positioned to take a portion of one of the fastest growing industries in the world.

Ciber, Inc. (NYSE: CBR)

With a valuation just shy of $250 million, Ciber is one of the bigger names on our list, and those familiar with IT services industry will likely already know the name. Founded in 1974 in response to the huge demand for computing consulting services at the time, the company now has 80 offices globally and employs upwards of 6,500 people in 15 countries. It does everything from application building to data analytics to consulting services, and had served more than 2000 blue chip companies in its lifetime.

All this does not mean that it isn’t undervalued. In each of the last three years Ciber has generated in excess of $850 million in revenues, and during the nine months to September last year, recorded just shy of $600 million.

Despite this, it’s down 25% on 2015 highs, and more than 90% on all time highs. The latter were recorded in 1998, so take them with a pinch of salt, but it demonstrates that with the right market sentiment, this company can grow exponentially. The long and short of it is that any company valued at one third its annual revenues, in an industry set to explode, is one to keep a close eye on.

NCI, Inc. (NASDAQ: NCIT)

This one is a military tech play. NCI generates 70% of its revenues from Department of Defense contracts in the US, with services that range from data analysis of its weapons systems to hardware and application integration. It submits proposals each year with total values in excess of $1 billion, and expects to have generated $335 million during full year 2015, up from the $317 million recorded in 2014 and the $332 million recorded in 2014. It’s the only company in this list that generates net income, recorded as $7.7 million and $8.5 million during 2013 and 2014 respectively, and expects a bottom line of $10.6 million during 2015 – $0.78 per share on count of 13.6 million shares.

The company just picked up two prestigious recommendations, the Victory Media’s 2016 Military Friendly Employers List and CMMI-DEV Maturity Level 3, and a $9 million US Air Force contract that will see guaranteed payment this year, and an option to extend for a further four years.

Its current market valuation is only $162 million. NCI is down 28% from 2015 highs, against a backdrop of wider market weakness, despite its continued revenue growth and bottom line improvements. When markets pick up, this move could well prove a temporary correction and an opportunity to get into this small cap tech company at a discount.

Any one of these companies could become an acquisition target considering the numbers involved, especially as competition in the space heats up and industry leaders look for a competitive edge in new technologies.

Market Exclusive is not an investment advisor. Read our full disclaimer here.

The post As Big Data Coalesces, Watch out for Some Roll-Up appeared first on Market Exclusive.

SOURCE: Market Exclusive

ReleaseID: 437696